HRP20040408A2 - New anhydrous crystalline forms of gabapentin - Google Patents
New anhydrous crystalline forms of gabapentin Download PDFInfo
- Publication number
- HRP20040408A2 HRP20040408A2 HR20040408A HRP20040408A HRP20040408A2 HR P20040408 A2 HRP20040408 A2 HR P20040408A2 HR 20040408 A HR20040408 A HR 20040408A HR P20040408 A HRP20040408 A HR P20040408A HR P20040408 A2 HRP20040408 A2 HR P20040408A2
- Authority
- HR
- Croatia
- Prior art keywords
- gabapentin
- anhydrous form
- fact
- crystalline
- whose
- Prior art date
Links
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 title claims description 76
- 229960002870 gabapentin Drugs 0.000 title claims description 36
- WRSFRDZQQUAKNA-UHFFFAOYSA-N 2-[1-(aminomethyl)cyclohexyl]acetic acid;hydrate Chemical compound O.OC(=O)CC1(CN)CCCCC1 WRSFRDZQQUAKNA-UHFFFAOYSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 8
- 230000005855 radiation Effects 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 7
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims description 6
- 239000007790 solid phase Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- YUWFEBAXEOLKSG-UHFFFAOYSA-N hexamethylbenzene Chemical compound CC1=C(C)C(C)=C(C)C(C)=C1C YUWFEBAXEOLKSG-UHFFFAOYSA-N 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000011877 solvent mixture Substances 0.000 claims description 3
- 239000002274 desiccant Substances 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims 2
- 238000006297 dehydration reaction Methods 0.000 claims 2
- 239000012071 phase Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 7
- 150000004682 monohydrates Chemical class 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- -1 compound gabapentin monohydrate Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- XBUDZAQEMFGLEU-UHFFFAOYSA-N 2-[1-(aminomethyl)cyclohexyl]acetic acid;hydron;chloride Chemical compound Cl.OC(=O)CC1(CN)CCCCC1 XBUDZAQEMFGLEU-UHFFFAOYSA-N 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910052581 Si3N4 Inorganic materials 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000007792 gaseous phase Substances 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000010887 waste solvent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
- C07C227/42—Crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32837501P | 2001-10-09 | 2001-10-09 | |
| US10/256,155 US6800782B2 (en) | 2001-10-09 | 2002-09-25 | Anhydrous crystalline forms of gabapentin |
| PCT/US2002/031706 WO2003031391A1 (en) | 2001-10-09 | 2002-10-03 | New anhydrous crystalline forms of gabapentin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20040408A2 true HRP20040408A2 (en) | 2004-10-31 |
Family
ID=26945177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20040408A HRP20040408A2 (en) | 2001-10-09 | 2004-05-07 | New anhydrous crystalline forms of gabapentin |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6800782B2 (es) |
| EP (1) | EP1463712A1 (es) |
| JP (1) | JP2005505594A (es) |
| KR (1) | KR20050033525A (es) |
| CN (1) | CN1568305A (es) |
| AP (1) | AP2004003025A0 (es) |
| BG (1) | BG108702A (es) |
| BR (1) | BR0213156A (es) |
| CA (1) | CA2462331A1 (es) |
| CO (1) | CO5570697A2 (es) |
| CZ (1) | CZ2004416A3 (es) |
| EA (1) | EA006557B1 (es) |
| GE (1) | GEP20063936B (es) |
| HR (1) | HRP20040408A2 (es) |
| HU (1) | HUP0401782A3 (es) |
| IL (1) | IL161099A0 (es) |
| IS (1) | IS7195A (es) |
| MA (1) | MA27072A1 (es) |
| MX (1) | MXPA04003301A (es) |
| NO (1) | NO20041370L (es) |
| NZ (1) | NZ531993A (es) |
| OA (1) | OA12665A (es) |
| PL (1) | PL368117A1 (es) |
| RS (1) | RS28204A (es) |
| SK (1) | SK1572004A3 (es) |
| TN (1) | TNSN04055A1 (es) |
| WO (1) | WO2003031391A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070043236A1 (en) * | 2003-05-19 | 2007-02-22 | Chandiran Thakashina M | Process for preparation of gabapentin |
| WO2004106281A1 (en) * | 2003-05-30 | 2004-12-09 | Ranbaxy Laboratories Limited | Crystalline gabapentin |
| WO2004110342A2 (en) * | 2003-06-12 | 2004-12-23 | Matrix Laboratories Ltd | Novel polymorph of gabapentin and its conversion to gabapentin form-ii |
| US7169812B2 (en) * | 2003-07-01 | 2007-01-30 | Medtronic, Inc. | Process for producing injectable gabapentin compositions |
| ITMI20040579A1 (it) * | 2004-03-25 | 2004-06-25 | Zambon Spa | Processo di preparazione di gabapentina |
| WO2010023694A2 (en) * | 2008-09-01 | 2010-03-04 | Hikal Ltd | Crystalline forms of gabapentin and process thereof |
| CN104649921B (zh) * | 2015-01-14 | 2016-09-28 | 天津大学 | 一种加巴喷丁与己二酸共晶及其制备方法 |
| CN116693410B (zh) * | 2023-06-08 | 2024-06-07 | 浙江竹子制药有限公司 | 一种粒径可控的加巴喷丁制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4087544A (en) | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| JPS62247160A (ja) * | 1986-03-31 | 1987-10-28 | Aisin Seiki Co Ltd | スタ−リングエンジンの始動装置 |
| US4960931A (en) | 1988-05-02 | 1990-10-02 | Warner-Lambert Company | Gabapentin mohohydrate and a process for producing the same |
| US4894476A (en) | 1988-05-02 | 1990-01-16 | Warner-Lambert Company | Gabapentin monohydrate and a process for producing the same |
| DE3928184A1 (de) | 1989-08-25 | 1991-02-28 | Goedecke Ag | Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte |
| IL119890A (en) | 1996-12-24 | 2002-03-10 | Teva Pharma | Gabapentin form iii and preparation of gabapentin form ii |
| ES2137137B1 (es) | 1998-05-25 | 2000-08-16 | Medichem Sa | Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica. |
-
2002
- 2002-09-25 US US10/256,155 patent/US6800782B2/en not_active Expired - Fee Related
- 2002-10-03 BR BR0213156-0A patent/BR0213156A/pt not_active IP Right Cessation
- 2002-10-03 NZ NZ531993A patent/NZ531993A/en unknown
- 2002-10-03 GE GE5594A patent/GEP20063936B/en unknown
- 2002-10-03 IL IL16109902A patent/IL161099A0/xx unknown
- 2002-10-03 EA EA200400417A patent/EA006557B1/ru not_active IP Right Cessation
- 2002-10-03 SK SK157-2004A patent/SK1572004A3/sk not_active Application Discontinuation
- 2002-10-03 CZ CZ2004416A patent/CZ2004416A3/cs unknown
- 2002-10-03 OA OA1200400095A patent/OA12665A/en unknown
- 2002-10-03 EP EP02766485A patent/EP1463712A1/en not_active Withdrawn
- 2002-10-03 JP JP2003534375A patent/JP2005505594A/ja active Pending
- 2002-10-03 RS YU28204A patent/RS28204A/sr unknown
- 2002-10-03 PL PL02368117A patent/PL368117A1/xx not_active Application Discontinuation
- 2002-10-03 HU HU0401782A patent/HUP0401782A3/hu unknown
- 2002-10-03 AP APAP/P/2004/003025A patent/AP2004003025A0/en unknown
- 2002-10-03 WO PCT/US2002/031706 patent/WO2003031391A1/en active Application Filing
- 2002-10-03 CN CNA02820056XA patent/CN1568305A/zh active Pending
- 2002-10-03 MX MXPA04003301A patent/MXPA04003301A/es active IP Right Grant
- 2002-10-03 KR KR1020047005149A patent/KR20050033525A/ko not_active Application Discontinuation
- 2002-10-03 CA CA002462331A patent/CA2462331A1/en not_active Abandoned
-
2004
- 2004-03-23 IS IS7195A patent/IS7195A/is unknown
- 2004-04-01 NO NO20041370A patent/NO20041370L/no not_active Application Discontinuation
- 2004-04-05 MA MA27606A patent/MA27072A1/fr unknown
- 2004-04-06 CO CO04032599A patent/CO5570697A2/es not_active Application Discontinuation
- 2004-04-07 TN TNP2004000055A patent/TNSN04055A1/fr unknown
- 2004-04-28 BG BG108702A patent/BG108702A/xx unknown
- 2004-05-07 HR HR20040408A patent/HRP20040408A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0213156A (pt) | 2004-09-14 |
| HUP0401782A2 (hu) | 2005-10-28 |
| MXPA04003301A (es) | 2004-07-23 |
| RS28204A (en) | 2006-12-15 |
| CN1568305A (zh) | 2005-01-19 |
| NO20041370L (no) | 2004-04-01 |
| AP2004003025A0 (en) | 2004-06-30 |
| IL161099A0 (en) | 2004-08-31 |
| MA27072A1 (fr) | 2004-12-20 |
| BG108702A (en) | 2005-05-31 |
| GEP20063936B (en) | 2006-10-10 |
| TNSN04055A1 (fr) | 2006-06-01 |
| CO5570697A2 (es) | 2005-10-31 |
| CA2462331A1 (en) | 2003-04-17 |
| PL368117A1 (en) | 2005-03-21 |
| EA006557B1 (ru) | 2006-02-24 |
| NZ531993A (en) | 2006-09-29 |
| WO2003031391A1 (en) | 2003-04-17 |
| JP2005505594A (ja) | 2005-02-24 |
| US20030092933A1 (en) | 2003-05-15 |
| US6800782B2 (en) | 2004-10-05 |
| KR20050033525A (ko) | 2005-04-12 |
| SK1572004A3 (sk) | 2005-03-04 |
| EP1463712A1 (en) | 2004-10-06 |
| HUP0401782A3 (en) | 2006-01-30 |
| IS7195A (is) | 2004-03-23 |
| OA12665A (en) | 2006-06-19 |
| CZ2004416A3 (cs) | 2005-03-16 |
| EA200400417A1 (ru) | 2004-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6114849B2 (ja) | プリン誘導体の結晶性形態 | |
| US4935507A (en) | Crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) | |
| RU2615509C2 (ru) | Кристаллическая 7-{ (3s,4s)-3-[(циклопропиламино)метил]-4-фторпирролидин-1-ил} -6-фтор-1-(2-фторэтил)-8-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновая кислота | |
| CZ2015504A3 (cs) | Krystalické formy obeticholové kyseliny | |
| WO2009114181A2 (en) | Substituted heterocycle fused gamma-carbolines solid | |
| HRP20040408A2 (en) | New anhydrous crystalline forms of gabapentin | |
| KR20040008175A (ko) | 5,8,14-트리아자테트라시클로(10.3.1.02,11.04,9)-헥사데카-2(11),3,5,7,9-펜타엔의 시트르산염 및 그의 제약 조성물 | |
| CA2814357C (en) | Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoropiperidin-2-one tartrate | |
| MX2011004950A (es) | Metodo para preparar una forma cristalina no hidratable. | |
| NZ527455A (en) | Polymorphs of zaleplon and methods for the preparation thereof | |
| JP6276702B2 (ja) | （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ−［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミン塩酸塩の固体形態 | |
| WO2015078424A1 (en) | Crystalline forms of vemurafenib | |
| NL8203688A (nl) | Nieuwe kristalmodificatie van cimetidine, alsmede werkwijze voor de bereiding ervan. | |
| US20180370926A1 (en) | Process of preparing tyrosine kinase inhibitor | |
| EP3484471B1 (en) | Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide | |
| JP2004517799A (ja) | ６−（４−クロロフェニル）−２，２−ジメチル−７−フェニル−２，３−ジヒドロ−１ｈ−ピロリジン−５−イル酢酸の製造法 | |
| TWI567078B (zh) | （１ｒ，４ｒ）－６’－氟－（Ｎ，Ｎ－二甲基）－４－苯基－４’，９’－二氫－３’Ｈ－螺－［環己烷－１，１’－吡喃並－［３，４，b］吲哚］－４－胺及硫酸之固體形式 | |
| WO2016034602A1 (en) | Solid forms of (2s,4r)-4-[4-(1-methyl-1h-pyrazol-4-yl)-2-trifluoromethyl-benzenesulfonyl]-1-(1-trifluoromethyl-cyclopropanecarbonyl)-pyrrolidine-2-carboxylic acid (1-cyano-cyclopropyl)-amide | |
| AU2002330220A1 (en) | New anhydrous crystalline forms of gabapentin | |
| KR20240135640A (ko) | 뉴로키닌-1 길항제 전구약물 화합물의 결정형 | |
| UA77021C2 (en) | A method for the preparation of crystalline dehydrate of gabapentin of form b, crystalline dehydrates of gabapentin of form a and form b | |
| Kobayashi et al. | Physicochemical analyses of phase transition and dehydration processes of a new oral 1β-methylcarbapenem antibiotic agent, CS-834 | |
| JP2005519934A (ja) | エリスロマイシン誘導体の非水和物／水和物およびその非水和物／水和物を製造する方法 | |
| JPH0249752A (ja) | テトラキス〔３―（３，５―ジ第３級ブチル―４―ヒドロキシフェニル）プロピオニルオキシメチル〕メタンのβ晶の晶出精製方法 | |
| WO2012143932A1 (en) | Crystalline strontium ranelate form-s |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20070928 Year of fee payment: 6 |
|
| OBST | Application withdrawn |